Asia-Pacific Pharmaceutical Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The asia-Pacific pharmaceutical packaging market size is expected to grow from USD 44.57 billion in 2025 to USD 47.52 billion in 2026 and is forecast to reach USD 65.48 billion by 2031 at 6.62% CAGR over 2026-2031. This report is Segmented by Material (Plastic, Paper and Paperboard, Glass, Aluminum Foil, and More), Type (Ampoules, Blister Packs, Plastic Bottles, Syringes, Vials, IV Fluids, Stick Packs, Pouches and Sachets, and Caps and Closures), Drug Delivery Mode (Oral, Injectable, Pulmonary, and More), and Country. The Market Forecasts are Provided in Terms of Value (USD).

Asia-Pacific Pharmaceutical Packaging Market Trends and Insights

Rising Biologics Pipeline Demanding High-Integrity Primary Packaging

Biologics capacity additions across Asia-Pacific have triggered unprecedented demand for vials and pre-filled syringes that combine low extractables, dimensional consistency, and compatibility with lyophilization cycles. Contract manufacturers align with originator expectations by insisting on ISO 15378-certified lines and validated ICH Q3D dossiers, tilting procurement toward incumbents able to produce data packs within 18-24 months. Polymer vials, such as cyclic olefin formats, are gaining share where protein adsorption or delamination risk is unacceptable, reshaping the materials mix of the Asia-Pacific pharmaceutical packaging market. The result is a virtuous cycle in which converters that invest early in polymer capacity secure multi-year supply agreements, locking in volumes before furnace-based glass capacity can catch up. As pipeline molecules move from clinical to commercial scale, regional demand for high-integrity containers is set to rise steadily through the decade.

Accelerated Fill-Finish Outsourcing to Asia Driving Contract Packaging Volumes

Multinational drug makers have stepped up fill-finish transfers to India, China, and South Korea, attracted by cost savings and local market-access incentives. Each new suite energizes upstream demand for primary and secondary packs, typically bundling vials, stoppers, cartons, and serialization labels under a single master agreement. This dynamic reinforces consolidation, because contract manufacturers favor suppliers that can guarantee component compatibility and single-lot deliveries at cycle-time levels consistent with biologics turnarounds. In the Asia-Pacific pharmaceutical packaging market, the outsourcing wave translates into higher unit throughput and stricter service-level requirements, accelerating automation and the deployment of vision inspection across converter footprints. Suppliers unable to finance these upgrades risk displacement as large CDMOs streamline vendor bases to two or three qualified partners.

Stringent PVC Phase-Out Policies in Japan and South Korea

Environmental regulations in Japan and South Korea require the elimination of PVC in blisters by 2027-2028. Converters must re-engineer tooling because polypropylene and polyester films require new sealing windows and cavity geometries, leading to validation expenses that can reach half a million U.S. dollars per SKU. Drug formulators may need moisture scavengers, which can delay launches and complicate stability programs. Collectively, tool-change expenses, validation timelines, and material cost premiums weigh on growth potential in two high-value markets, restraining the regional CAGR of the Asia-Pacific pharmaceutical packaging market until compliant capacities settle.

Other drivers and restraints analyzed in the detailed report include:

• Government Bulk-Procurement Schemes Favoring Cost-Efficient Blister Formats
• Serialization Regulations Boosting Track-And-Trace Packaging
• Volatile Resin and Alumina Prices Squeezing Converter Margins

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Bioplastics and cyclic olefin copolymers, while small today, are the fastest-growing slice of the Asia-Pacific pharmaceutical packaging market size and are forecast to climb at 7.59% CAGR as biologics sponsors pivot to low-extractable containers. Glass remains dominant for long-shelf-life injectables, with two suppliers jointly holding a majority of Asia-Pacific pharmaceutical packaging market share in Type I borosilicate. Aluminum foil, pressured by input cost volatility, is simultaneously moving to 20 micron gauges and tighter pinhole specifications, raising the qualification bar.

Converters see a dual-track future. Premium resin-based vials and cyclic olefin syringes capture value where biologic stability demands trump cost. Standard PET bottles and HDPE closures still anchor oral formulations but face extended producer-responsibility levies in Japan and South Korea. Paperboard cartons, commoditized yet essential, are streamlining dimensions for line-speed efficiency. The outcome is a material landscape where technical barriers, not volume alone, decide profitability.

Complete Report Scope:

• By Material
  • Plastic
  • Paper and Paperboard
  • Glass
  • Aluminum Foil
  • Other Materials (Bioplastics, Cyclic Olefins)
• By Type
  • Ampoules
  • Blister Packs
  • Plastic Bottles
  • Syringes
  • Vials
  • IV Fluids
  • Stick Packs
  • Pouches and Sachets
  • Caps and Closures
• By Drug Delivery Mode
  • Oral
  • Injectable
  • Pulmonary
  • Topical and Transdermal
  • Other Modes
• By Country
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific

List of Companies Covered in this Report:

• Amcor Plc
• Gerresheimer AG
• Schott AG
• West Pharmaceutical Services Inc
• CCL Industries Inc
• NIPRO Corporation
• Wihuri Group
• Klockner Pentaplast Group
• Catalent Pharma Solutions Inc
• Berry Global Group Inc
• SGD Pharma
• AptarGroup Inc
• Stevanato Group
• Huhtamaki Oyj
• Daikyo Seiko Ltd
• Shandong Pharmaceutical Glass Co
• Tekni-Plex Inc
• Alpla Werke
• Chongqing Zhengchuan Glass
• Essel Propack Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support